Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Strosberg, J. R., Al-Toubah, T., El-Haddad, G. Tags: Letters Source Type: research

Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Wee, C. E., Dundar, A., Eiring, R. A., Badawy, M., Hobday, T. J., Kendi, A. T., Packard, A. T., Halfdanarson, T. R. Tags: Letters Source Type: research

Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging
We describe a unique case of a patient presenting with unilateral mild paresis, slowing of the upper limb, and parkinsonism, who underwent a full imaging work-up including MRI, 123I-FP-CIT PET, 18F-FE-PE2I PET, and 18F-FDG PET. This case demonstrates that imaging may aid substantially in the diagnostic work-up of complex neurologic disorders. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Masrori, P., Van Weehaeghe, D., Van Laere, K., Van Damme, P. Tags: Challenging Case Studies Source Type: research

Optical Navigation of the Drop-In {gamma}-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
Conclusion: Optical navigation of the Drop-In probe provides a next step toward connecting nuclear medicine with robotic surgery. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Azargoshasb, S., Houwing, K. H. M., Roos, P. R., van Leeuwen, S. I., Boonekamp, M., Mazzone, E., Bauwens, K., DellOglio, P., van Leeuwen, F. W. B., van Oosterom, M. N. Tags: Basic Source Type: research

Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
Conclusion: 18F-MNI-968 has significant potential as a D1R agonist PET radiotracer, and further characterization in human subjects is warranted. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Barret, O., Zhang, L., Alagille, D., Constantinescu, C. C., Sandiego, C., Papin, C., Sullivan, J. M., Morley, T., Carroll, V. M., Seibyl, J., Chen, J., Lee, C., Villalobos, A., Gray, D., McCarthy, T. J., Tamagnan, G. Tags: Basic Source Type: research

Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
When one is interpreting clinical 18F-FDG PET scans of the brain (excluding tumors) in children, the typical abnormality seen is hypometabolism of various brain regions. Focal areas of hypermetabolism are noted occasionally, and the usual interpretation is that the hypermetabolic region represents a seizure focus. In this review, I discuss and illustrate the multiple causes of hypermetabolism on 18F-FDG PET studies that should not be interpreted as seizure activity, as such an interpretation could potentially be incorrect. Various conditions in which focal hypermetabolism can be encountered on 18F-FDG PET studies include i...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Chugani, H. T. Tags: Clinical Source Type: research

TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
Conclusion: TauL as calculated by TauIQ provides a superior approach for the quantification of tau PET data. In particular, it provides a substantial improvement in power for longitudinal analyses and the early detection of tau deposition and thus should have significant value for clinical imaging trials in AD that are investigating the attenuation of tau deposition with novel therapies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Whittington, A., Gunn, R. N., for the Alzheimers Disease Neuroimaging Initiative Tags: Clinical Source Type: research

Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
Hyperparathyroidism is an endocrine disorder caused by one or more hyperfunctioning parathyroid glands. Current imaging consisting of ultrasound and 99mTc-sestamibi is imprecise, making localization difficult. 18F-fluorocholine (18F-FCH) PET has recently shown promise in presurgical localization of parathyroid adenomas. The primary aim of this study was to summarize the sensitivities and specificities of studies using 18F-FCH PET to localize hyperparathyroidism. A secondary aim was to summarize a subset of studies in which 99mTc-sestamibi scans were also used and to compare the performance of the 2 modalities. Methods: We ...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Whitman, J., Allen, I. E., Bergsland, E. K., Suh, I., Hope, T. A. Tags: Endocrinology Source Type: research

Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
Conclusion: The NETPET score is a prognostic biomarker in bronchial NENs as well as GEPNENs. Although it needs to be validated in prospective studies, it holds significant promise as a biomarker for a wide range of NENs. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Chan, D. L., Ulaner, G. A., Pattison, D., Wyld, D., Ladwa, R., Kirchner, J., Li, B. T., Lai, W. V., Pavlakis, N., Roach, P. J., Bailey, D. L. Tags: Clinical Source Type: research

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Conclusion: These findings demonstrate the feasibility of using organ dose for a phase 1 escalation design and suggest the safety of using 90Y-DOTATOC and 131I-MIBG. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Bushnell, D. L., Bodeker, K. L., ODorisio, T. M., Madsen, M. T., Menda, Y., Graves, S., Zamba, G. K. D., ODorisio, M. S. Tags: Clinical Source Type: research

Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Markowski, M. C., Velho, P. I., Eisenberger, M. A., Pomper, M. G., Pienta, K. J., Gorin, M. A., Antonarakis, E. S., Denmeade, S. R., Rowe, S. P. Tags: Clinical Source Type: research

SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
Conclusion: For 18F-DCFPyL PET/CT, SUVpeak correlates strongly with TBR. Therefore, it is a valuable simplified, semiquantitative measurement in patients with low-volume PCa (
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Bodar, Y. J. L., Koene, B. P. F., Jansen, B. H. E., Cysouw, M. C. F., Meijer, D., Hendrikse, N. H., Vis, A. N., Boellaard, R., Oprea-Lager, D. E. Tags: Clinical Source Type: research

Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is critical for prognosis and patient management. Both prostate-specific membrane antigen (PSMA) PET/CT and ferumoxtran-10 nanoparticle–enhanced MRI (nano-MRI) are imaging modalities with high potential to identify LN metastases in PCa patients. The aim of this study was to compare the results of these imaging technologies in terms of characteristics and anatomic localization of suspicious LNs in order to assess the feasibility of their complementary use for imaging in PCa patients. Methods: In total, 45 patients with either primary P...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Schilham, M. G. M., Zamecnik, P., Prive, B. M., Israel, B., Rijpkema, M., Scheenen, T., Barentsz, J. O., Nagarajah, J., Gotthardt, M. Tags: Clinical Source Type: research

Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
We examined 132 patients (76 with the old protocol and 56 with the new one) with respect to urinary bladder activity (SUVmean), prostate cancer lesion uptake (SUVmax), and lesion contrast (ratio of tumor SUVmax to bladder SUVmean for local relapses and ratio of tumor SUVmax to gluteal-muscle SUVmean for nonlocal prostate cancer lesions). Results: Bladder activity was significantly greater for the old protocol in the late scans than for the new protocol (ratio of bladder activity at 2.5 h to bladder activity at 1.5 h, 2.33 ± 1.17 vs. 1.37 ± 0.50, P
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Alberts, I., Niklas-Hunermund, J., Sachpekidis, C., Zacho, H. D., Mingels, C., Dijkstra, L., Bohn, K. P., Lappchen, T., Gourni, E., Rominger, A., Afshar-Oromieh, A. Tags: Clinical Source Type: research

The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
The prostate-specific membrane antigen (PSMA) has been targeted for PET imaging and radioligand therapy (RLT) in patients with prostate cancer. Xerostomia is a common side effect of RLT because of the high salivary gland uptake of PSMA radioligands. Here, we aimed to determine the impact of monosodium glutamate (MSG) administration on PSMA-radioligand biodistribution within healthy organs and tumor lesions by using 68Ga-PSMA-11 PET imaging. Methods: Sixteen men with prostate cancer were randomized (1:1) into oral ingestion and oral topical application ("swishing") arms. Each subject underwent 2 68Ga-PSMA-11 PET/C...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Armstrong, W. R., Gafita, A., Zhu, S., Thin, P., Nguyen, K., Alano, R., Lira, S., Booker, K., Gardner, L., Grogan, T., Elashoff, D., Allen-Auerbach, M., Dahlbom, M., Czernin, J., Calais, J. Tags: Clinical Source Type: research

PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Brenner, W., Strobel, J., Prasad, V. Tags: Clinical Source Type: research

68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma
Conclusion: 68Ga-PSMA-11 PET demonstrated higher accuracy than CT in the detection of HCC metastases and was associated with a management change in about half the patient cohort. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Hirmas, N., Leyh, C., Sraieb, M., Barbato, F., Schaarschmidt, B. M., Umutlu, L., Nader, M., Wedemeyer, H., Ferdinandus, J., Rischpler, C., Herrmann, K., Costa, P. F., Lange, C. M., Weber, M., Fendler, W. P. Tags: Clinical Source Type: research

Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Conclusion: 68Ga-BMS-986192 enables easy radiosynthesis and shows excellent in vitro and in vivo PD-L1–targeting characteristics. The high tumor uptake combined with low background accumulation at early imaging time points demonstrates the feasibility of 68Ga-BMS-986192 for imaging of PD-L1 expression in tumors and is encouraging for further clinical applications of PD-L1 ligands. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Robu, S., Richter, A., Gosmann, D., Seidl, C., Leung, D., Hayes, W., Cohen, D., Morin, P., Donnelly, D. J., Lipovšek, D., Bonacorsi, S. J., Smith, A., Steiger, K., Aulehner, C., Krackhardt, A. M., Weber, W. A. Tags: Basic Source Type: research

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
Conclusion: This post hoc study demonstrates that anti–carcinoembryonic antigen immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than 18F-DOPA PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Bodet-Milin, C., Faivre-Chauvet, A., Carlier, T., Ansquer, C., Rauscher, A., Frampas, E., Toulgoat, F., Masson, D., Bourgeois, M., Cerato, E., Rohmer, V., Couturier, O., Drui, D., Goldenberg, D. M., Sharkey, R. M., Barbet, J., Kraeber-Bodere, F. Tags: Clinical Source Type: research

Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study
Breast cancer (BC) is a heterogeneous disease in which estrogen receptor (ER) expression plays an important role in most tumors. A clinical dilemma may arise when a metastasis biopsy to determine the ER status cannot be performed safely or when ER heterogeneity is suspected between tumor lesions. Whole-body ER imaging, such as 16α-18F-fluoro-17β-estradiol (18F-FES) PET, may have added value in these situations. However, the role of this imaging technique in routine clinical practice remains to be further determined. Therefore, we assessed whether the physician’s remaining clinical dilemma after the standar...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Boers, J., Loudini, N., Brunsch, C. L., Koza, S. A., de Vries, E. F. J., Glaudemans, A. W. J. M., Hospers, G. A. P., Schroder, C. P. Tags: Clinical Source Type: research

Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors
Conclusion: Women and URiMs are underrepresented in NM training programs. This diversity gap is more pronounced among NM faculty and to an even greater extent in leadership positions. A greater proportion of NM trainees are international medical graduates compared with NM faculty members, suggesting declining NM recruitment among U.S. grads. NM is included in the medical school curriculum at fewer than one third of academic centers with NM residency programs, typically toward the end of medical school. Increased and earlier exposure to NM, especially for women and URiMs, may improve recruitment and mitigate diversity gaps....
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Cheng, J. L., Dibble, E. H., Baird, G. L., Gordon, L. L., Hyun, H. Tags: Issues and Controversies Source Type: research

Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
The principle of pretargeted radioimmunoimaging and therapy has been investigated over the past 30 y in preclinical and clinical settings with the aim of reducing the radiation burden of healthy tissue for antibody-based nuclear medicine techniques. In the past few decades, 4 pretargeting methodologies have been proposed, and 2 of them—the bispecific antibody–hapten and the streptavidin–biotin platforms—have been evaluated in humans in phase 1 and 2 studies. With this review article, we aim to survey clinical pretargeting studies in order to understand the challenges that these platforms have faced ...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Jallinoja, V. I. J., Houghton, J. L. Tags: Focus on Molecular Imaging Source Type: research

Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
Whereas benign pheochromocytomas and paragangliomas are often successfully cured by surgical resection, treatment of metastatic disease can be challenging in terms of both disease control and symptom control. Fortunately, several options are available, including chemotherapy, radiation therapy, and surgical debulking. Radiolabeled metaiodobenzylguanidine (MIBG) and somatostatin receptor imaging have laid the groundwork for use of these radiopharmaceuticals as theranostic agents. 131I-MIBG therapy of neuroendocrine tumors has a long history, and the recent approval of high-specific-activity 131I-MIBG for metastatic or inope...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Carrasquillo, J. A., Chen, C. C., Jha, A., Pacak, K., Pryma, D. A., Lin, F. I. Tags: Continuing Education Source Type: research

Why Will PET Be the Future of Nuclear Cardiology?
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Di Carli, M. F. Tags: Hot Topics Source Type: research

Image-Guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?
Image-guided high-intensity focused ultrasound (HIFU) has been increasingly used in medicine over the past few decades, and several systems for such have become commercially available. HIFU has passed regulatory approval around the world for the ablation of various solid tumors, the treatment of neurologic diseases, and the palliative management of bone metastases. The mechanical and thermal effects of focused ultrasound provide a possibility for histotripsy, supportive radiation therapy, and targeted drug delivery. The integration of imaging modalities into HIFU systems allows for precise temperature monitoring and accura...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Zhang, X., Landgraf, L., Bailis, N., Unger, M., Jochimsen, T. H., Melzer, A. Tags: State of the Art Source Type: research

Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Czernin, J., Radu, C., Ribas, A. Tags: Discussions with Leaders Source Type: research

The Annual Journal Impact Factor Saga
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Czernin, J. Tags: Editor ' s Page Source Type: research

Newsbriefs
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

Progress in Prostate Cancer Theranostics
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Wahl, R. L. Tags: SNMMI Newsline Source Type: research

ABNM Celebrating 50 Years
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Segall, G. M. Tags: SNMMI Newsline Source Type: research

FDA Encourages Inclusion of Incurable Cancers in Trials
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

JNM 2020 Impact Factor Rises Sharply
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

This Month in JNM
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Tags: This Month in JNM Source Type: research

SNMMI Newsline
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

Errata
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Tags: Errata Source Type: research

Postinfectious Neurologic Complications in COVID-19: A Complex Case Report
A 40-y-old woman with severe acute respiratory syndrome coronavirus 2 infection developed neurologic manifestations (confusion, agitation, seizures, dyskinesias, and parkinsonism) a few weeks after the onset of severe acute respiratory syndrome. MRI and cerebrospinal fluid analyses were unremarkable, but 18F-FDG PET/CT showed limbic and extralimbic hypermetabolism. A full recovery, alongside 18F-FDG normalization in previously hypermetabolic areas, was observed after intravenous immunoglobulin administration. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Tiraboschi, P., Xhani, R., Zerbi, S. M., Corso, A., Martinelli, I., Fusi, L., Grampa, G., Lombardo, A., Cavalcante, P., Cappelletti, C., Andreetta, F., Sironi, A., Redolfi, A., Muscio, C. Tags: Clinical (neurology) Source Type: research

Mapping Arginase Expression with 18F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary {alpha}-Amino Acids
Conclusion: The new 18F-fluorinated arginase inhibitors have the potential to map increased arginase expression related to inflammatory and tumorigenic processes. 18F-FBMARS showed the highest arginase-mediated uptake in PET imaging and a significant difference between uptake in control and arginase-inhibited PC3 xenografted mice. These results encourage further research to examine the suitability of 18F-FBMARS for selecting patients for treatments with arginase inhibitors. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Clemente, G. S., Antunes, I. F., Kurhade, S., van den Berg, M. P. M., Sijbesma, J. W. A., van Waarde, A., Buijsman, R. C., Willemsen-Seegers, N., Gosens, R., Meurs, H., Domling, A., Elsinga, P. H. Tags: Basic Science Investigations Source Type: research

Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism
Conclusion: Kinetic analysis of dynamic 18F-Gln-PET images demonstrated the ability to measure VD to estimate glutamine pool size, a key indicator of cellular glutamine metabolism, by both a 1-compartment model and Logan analysis. Changes in VD with glutaminase inhibition support the ability to assess response to glutamine metabolism-targeted therapy. Concordance of kinetic measures with tumor-to-blood ratios provides a clinically feasible approach to human imaging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Viswanath, V., Zhou, R., Lee, H., Li, S., Cragin, A., Doot, R. K., Mankoff, D. A., Pantel, A. R. Tags: Basic Science Investigations Source Type: research

Metallofluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI
Conclusion: Multimodal detection using FERM yields robust whole-body lesion detection and leverages the strengths of combined PET and 19F MRI. The FERM nanoemulsion has scalable production and is potentially useful for precise diagnosis, stratification, and treatment monitoring of inflammatory diseases. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Wang, C., Leach, B. I., Lister, D., Adams, S. R., Xu, H., Hoh, C., McConville, P., Zhang, J., Messer, K., Ahrens, E. T. Tags: Basic Science Investigations Source Type: research

Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16{beta}-18F-Fluoro-5{alpha}-Dihydrotestosterone
Conclusion: Despite its lower apparent molar activity, 18F-enzalutamide shows higher tumor uptake and better metabolic stability than 18F-FDHT and thus seems to have more favorable properties for imaging of AR with PET. However, further evaluation in other oncologic animal models and patients is warranted to confirm these results. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Antunes, I. F., Dost, R. J., Hoving, H. D., van Waarde, A., Dierckx, R. A. J. O., Samplonius, D. F., Helfrich, W., Elsinga, P. H., de Vries, E. F. J., de Jong, I. J. Tags: Featured Article of the Month Source Type: research

Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy
This article will also contrast currently available methods and tools with those used in the past, to propose a pathway whereby dosimetry helps the field by optimizing the biologic effect of the treatment and trial design in the drug approval process to reduce financial and logistical costs. We also briefly discuss the dosimetric equivalent of biomarkers to help bring a precision medicine approach to RPT implementation when merited by evidence collected during early-phase trial investigations. Advances in the methodology and related tools have made dosimetry the optimum biomarker for RPT. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Roncali, E., Capala, J., Benedict, S. H., Akabani, G., Bednarz, B., Bhadrasain, V., Bolch, W. E., Buchsbaum, J. C., Coleman, N. C., Dewaraja, Y. K., Frey, E., Ghaly, M., Grudzinski, J., Hobbs, R. F., Howell, R. W., Humm, J. L., Kunos, C. A., Larson, S., L Tags: Special Contributions Source Type: research

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases
Conclusion: 177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Fernandez, R., Eppard, E., Lehnert, W., Jimenez-Franco, L. D., Soza-Ried, C., Ceballos, M., Ribbeck, J., Kluge, A., Rosch, F., Meckel, M., Zhernosekov, K., Kramer, V., Amaral, H. Tags: Clinical Investigations Source Type: research

A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE
Conclusion: Mixed models based on a historical cohort of patients with complete time–activity data and new patients with only 1 or 2 SPECT/CT scans demonstrate less bias on average and significantly fewer outliers when estimating kidney TIA, compared with popular reduced-time-point methods. Use of mixed models allows for reduction of the imaging burden while maintaining accuracy, which is crucial for clinical implementation of dosimetry-based treatment. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Devasia, T. P., Dewaraja, Y. K., Frey, K. A., Wong, K. K., Schipper, M. J. Tags: Clinical (Oncology: GU) Source Type: research

Simulation of Low-Dose Protocols for Myocardial Perfusion 82Rb Imaging
Conclusion: HfD imaging does not affect the quantitative diagnostic accuracy of 82Rb PET on 3-dimensional PET/CT systems and could be used clinically. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Lassen, M. L., Otaki, Y., Kavanagh, P., Miller, R. J. H., Berman, D. S., Slomka, P. J. Tags: Clinical Investigations Source Type: research

Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
Conclusion: Compared with 177Lu-PSMA I&T, 19F/177Lu-rhPSMA-7.3 can be considered a suitable candidate for clinical translation because it has similar clearance kinetics and a similar radiation dose to healthy organs but superior tumor uptake and retention. Preliminary treatment experiments showed a favorable antitumor response. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Yusufi, N., Wurzer, A., Herz, M., DAlessandria, C., Feuerecker, B., Weber, W., Wester, H.-J., Nekolla, S., Eiber, M. Tags: Basic Science Investigations Source Type: research

Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
Conclusion: Because of its favorable toxicity profile and its uptake in HER2-positive lesions, this radiopharmaceutical can offer new therapeutic options to patients who have progressed on trastuzumab, pertuzumab, or trastuzmab emtansine, given its difference in mode-of-action. A dose escalation is planned in a subsequent phase I/II study to assess the therapeutic window of this compound (NCT04467515). (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: DHuyvetter, M., Vos, J. D., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., Aa, F. v. d., Hendrikse, N. H., Eersels, J. L. E., Everaert, H., Gykiere, P., Devoogdt, N., Raes, G., Lahoutte, T., Keyae Tags: Clinical Investigations Source Type: research

Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
Imaging with novel PET radiotracers has significantly influenced radiotherapy decision making and radiation planning in patients with recurrent prostate cancer (PCa). The purpose of this analysis was to report the final results for management decision changes based on 18F-fluciclovine PET/CT findings and determine whether the decision change trend remained after completion of accrual. Methods: Patients with detectable prostate-specific antigen (PSA) after prostatectomy were randomized to undergo either conventional imaging (CI) only (arm A) or CI plus 18F-fluciclovine PET/CT (arm B) before radiotherapy. In arm B, positivit...
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Abiodun-Ojo, O. A., Jani, A. B., Akintayo, A. A., Akin-Akintayo, O. O., Odewole, O. A., Tade, F. I., Joshi, S. S., Master, V. A., Fielder, B., Halkar, R. K., Zhang, C., Goyal, S., Goodman, M. M., Schuster, D. M. Tags: Clinical Investigations Source Type: research

Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of prostate cancer theranostic agents. 18F-rhPSMA-7 offers the advantages of 18F labeling and low urinary excretion compared with 68Ga-PSMA-11. Here, we compare the frequency of non–tumor-related uptake and tumor positivity with 68Ga-PSMA-11 and 18F-rhPSMA-7 in patients with primary or recurrent prostate cancer. Methods: This retrospective matched-pair comparison matched 160 18F-rhPSMA-7 with 160 68Ga-PSMA-11 PET/CT studies for primary staging (n = 33) and biochemical recurrence (n = 127) according to clinical characteristics. Two nuclear...
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Kroenke, M., Mirzoyan, L., Horn, T., Peeken, J. C., Wurzer, A., Wester, H.-J., Makowski, M., Weber, W. A., Eiber, M., Rauscher, I. Tags: Clinical Investigations Source Type: research

Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study
Conclusion: Effective doses of 99mTc-PSMA I&S were comparable to those known for most of the 99mTc tracers and was lower than for the 68Ga-labeled and 18F-labeled agents. 99mTc-PSMA I&S SPECT/CT showed high TBR in PCa patients. This study can provide required data for translation and approval of 99mTc-PSMA I&S by regulatory agencies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Urban, S., Meyer, C., Dahlbom, M., Farkas, I., Sipka, G., Besenyi, Z., Czernin, J., Calais, J., Pavics, L. Tags: Clinical Investigations Source Type: research

Interim PET in Diffuse Large B-Cell Lymphoma
Conclusion: Continuous scales are better suited for interim PET–based outcome prediction than the ordinal Deauville scale. qPET and SUVmax essentially carry the same information. The proportion of poor-risk patients identified is less than 15%. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 30, 2021 Category: Nuclear Medicine Authors: Kurch, L., Huttmann, A., Georgi, T. W., Rekowski, J., Sabri, O., Schmitz, C., Kluge, R., Duhrsen, U., Hasenclever, D. Tags: Clinical Investigations Source Type: research